Skip to content
Pay Bill
Careers
News
Make a Referral
Giving
Phone Numbers
    Request an Appointment
    ,

    Insulin Resistance Intervention after Stroke Trial (IRIS): A StrokeNet Study

    < 1
    min. read

    Insulin Resistance Intervention after Stroke Trial (IRIS): A StrokeNet Study

    The Insulin Resistance Intervention after Stroke Trial (IRIS) was a randomized, double-blind, placebo-controlled trial that is testing the hypothesis that reducing insulin resistance and its sequelae with thiazolidinedione therapy will prevent stroke and myocardial infarction among patients with a recent ischemic stroke or transient ischemic attack. Pioglitazone reduced the relative risk of the primarily outcome (fatal & non-fatal stroke and MI) by 24% (p=0.007) vs. placebo.

    Project Type: Research

    Year started: 2016

    Diagnosis: Stroke